{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:04:15Z","timestamp":1778223855766,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.hoc.2023.12.013","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T03:53:16Z","timestamp":1704945196000},"page":"511-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"38","author":[{"given":"Nadine","family":"Abdallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2023.12.013_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.013_bib2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2023.12.013_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-018-0065-8","article-title":"Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.013_bib4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.013_bib5","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2023.12.013_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor\u2013Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.013_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.013_bib8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1182\/blood.2020008209","article-title":"Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"137","author":"Dimopoulos","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2023.12.013_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.hoc.2023.12.013_bib10","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell\u2013Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2023.12.013_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.013_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.013_bib13","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2023.12.013_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/leu.2013.216","article-title":"The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma","volume":"28","author":"Touzeau","year":"2014","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.hoc.2023.12.013_bib15","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1182\/blood-2018-09-876433","article-title":"Variable BCL2\/BCL2L1 ratio in multiple myeloma with t(11;14)","volume":"132","author":"Cleynen","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.013_bib16","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.013_bib17","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.12.013_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","article-title":"Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models","volume":"15","author":"Punnoose","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"10.1016\/j.hoc.2023.12.013_bib19","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","article-title":"Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.12.013_bib20","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2023.12.013_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2021-145757","article-title":"Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.hoc.2023.12.013_bib22","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib23","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1182\/blood-2022-163809","article-title":"An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1\/2 Study of Patients with t(11;14) Relapsed\/Refractory Multiple Myeloma","volume":"140","author":"Kaufman","year":"2022","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2023.12.013_bib24","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","article-title":"Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Costa","year":"2021","journal-title":"Blood Advances"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.013_bib25","doi-asserted-by":"crossref","first-page":"TPS8554","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554","article-title":"A\u00a0phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma","volume":"38","author":"Mateos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.013_bib26","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.hoc.2023.12.013_bib27","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2023.12.013_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A\u00a0Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J\u00a0Med Chem"},{"issue":"13","key":"10.1016\/j.hoc.2023.12.013_bib29","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J\u00a0Med Chem"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib30","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","article-title":"Iberdomide (CC-220) Has Synergistic Anti-Tumor and Immunostimulatory Activity Against Multiple Myeloma in Combination with Both Bortezomib and Dexamethasone, or in Combination with Daratumumab in\u00a0Vitro","volume":"132","author":"Amatangelo","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2023.12.013_bib31","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.12.013_bib32","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2019-124345","article-title":"CC-92480, a Novel Cereblon E3 Ligase Modulator, Is Synergistic with Dexamethasone, Bortezomib, and Daratumumab in Multiple Myeloma","volume":"134","author":"Wong","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2023.12.013_bib33","doi-asserted-by":"crossref","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","article-title":"Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial","volume":"9","author":"Lonial","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.hoc.2023.12.013_bib34","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S2152-2650(21)02087-5","article-title":"OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"21","author":"Lonial","year":"2021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.013_bib35","doi-asserted-by":"crossref","first-page":"TPS8069","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069","article-title":"EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Lonial","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2023.12.013_bib36","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/JCO.2020.38.15_suppl.8500","article-title":"First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"38","author":"Richardson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib37","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137161","article-title":"Dose- and Schedule-Dependent Immunomodulatory Effects of the Novel Celmod Agent CC-92480 in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Wong","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib38","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2022-157945","volume":"140","author":"Richardson","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.12.013_bib39","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S2152-2650(22)00326-3","article-title":"OAB-053: Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"22","author":"Richardson","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.12.013_bib40","doi-asserted-by":"crossref","first-page":"TPS8070","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8070","article-title":"A\u00a0phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-2","volume":"41","author":"Amatangelo","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib41","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1182\/blood-2022-156387","article-title":"Modakafusp Alfa (TAK-573), a Novel CD38-Targeting Attenuated Interferon-Alpha Immunocytokine, Kills MM Cells Via NK Cell Activation","volume":"140","author":"Bruins","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-141219","article-title":"TAK-573, an Anti-CD38\/Attenuated Ifn\u03b1 Fusion Protein, Has Clinical Activity and Modulates the Ifn\u03b1 Receptor (IFNAR) Pathway in Patients with Relapsed\/Refractory Multiple Myeloma","volume":"136","author":"Vogl","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.12.013_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162472","article-title":"Targeting Attenuated Interferon-alpha to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity","volume":"11","author":"Pogue","year":"2016","journal-title":"PLoS One"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.12.013_bib44","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2022-162253","article-title":"Final Results from the First-in-Human Phase 1\/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"140","author":"Vogl","year":"2022","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823001806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T05:18:27Z","timestamp":1760591907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823001806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0889858823001806"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.013","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Therapies on the Horizon for Relapsed Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}